ClinicalTrials.gg
CompletedNCT05818956Updated Aug 6, 2024Results posted

A Study of TAK-227 in Healthy Adults

A Phase 1 interventional study of TAK-227 in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main aim of this study is to test the effects of food consumption with sponsor compound TAK-227 in healthy participants. The study will also measure side effects, and to check how much TAK-227 stays in the blood over time to work out the best dose.

Read the detailed description

The drug being tested in this study is called TAK-227. This study will assess the effect of food on single-dose of TAK-227 in healthy participants.

The study will enroll approximately 24 participants. A single dose of 50 milligram (mg) TAK-227 will be administered orally under one of 3 different feeding conditions.

  • Fasting (Treatment A),
  • Fed following a high-fat or high-calorie meal prior to dosing (Treatment B), and
  • Fed following a high-fat or high-calorie meal after dosing (Treatment C)

Participants will be randomly assigned to 1 of the 6 treatments sequences based on the 3 feeding conditions.

  • Sequence 1: (Treatment A + Treatment B + Treatment C)
  • Sequence 2: (Treatment B + Treatment C + Treatment A)
  • Sequence 3: (Treatment C + Treatment A + Treatment B)
  • Sequence 4: (Treatment A + Treatment C + Treatment B)
  • Sequence 5: (Treatment B + Treatment A + Treatment C)
  • Sequence 6: (Treatment C + Treatment B + Treatment A)

All participants will receive all 6 treatment regimens. This is a single-center trial. Participants will be followed up for up to 7 days after the last dose of study drug for a follow-up assessment. The overall time to participate in this study is approximately 40 days including screening period and follow-up period.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must fulfill the following inclusion criteria to be eligible for participation in the study:

  • (BMI) greater than or equal to (>=) 18 and less than or equal to (\<=) 32.0 kilogram per square meter (kg/m\^2) at screening visit.
  • Continuous non-smoker who has not used nicotine and tobacco containing products for at least 3 months prior to the first dosing based on participant self-reporting.

Exclusion criteria

Exclusion Criteria:

Participants must not be enrolled in the study if they meet any of the following criteria:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • Drink alcohol in excess of 21 units per week for males or 14 units per week for females, with one unit equal to (=) 150 milliliter (mL) of wine or 360 mL of beer or 45 mL of 45 percent (%) alcohol.
  • Positive results at screening for (HIV), surface antigen (HBsAg), or virus (HCV).
  • Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing and throughout the study. Medication listed as part of acceptable methods will be allowed. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to first study drug administration. Hormone replacement therapy will also be allowed.
    • Any drugs known to be significant inducers or inhibitors of Cytochrome P450 (CYP)3A4 enzymes and/or P-glycoprotein (gp), including St. John's Wort, within 28 days prior to the first dosing and throughout the study. Appropriate sources (example, Flockhart Table TM) will be consulted to confirm lack of pharmacokinetic (PK)/pharmacodynamics interaction with study drug.
    • Chronic use of non-steroidal anti-inflammatory (define as more that 7 days of use) within 2 weeks prior to screening and throughout the study.
  • Donation of blood or significant blood loss within 56 days prior to the first dosing.
  • Plasma donation within 7 days prior to the first dosing.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequence 1: (Treatment A + Treatment B + Treatment C)

    TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing.

    Drug: TAK-227

  • Experimental
    Sequence 2: (Treatment B + Treatment C + Treatment A)

    TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A . There will be a washout period of at least 4 days between each dosing.

    Drug: TAK-227

  • Experimental
    Sequence 3: (Treatment C + Treatment A + Treatment B)

    TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing.

    Drug: TAK-227

  • Experimental
    Sequence 4: (Treatment A + Treatment C + Treatment B)

    TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing.

    Drug: TAK-227

  • Experimental
    Sequence 5: (Treatment B + Treatment A + Treatment C)

    TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing.

    Drug: TAK-227

  • Experimental
    Sequence 6: (Treatment C + Treatment B + Treatment A)

    TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A. There will be a washout period of at least 4 days between each dosing.

    Drug: TAK-227

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for TAK-227

    Time frame: Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose

  2. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-227

    Time frame: Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose

  3. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-227

    Time frame: Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose

Secondary outcomes

  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant who had signed the informed consent form (ICF) to participate in a study; it did not necessarily have to have a causal relationship with the treatment. An SAE was any untoward medical occurrence that at any dose met one or more of the following criteria: resulted in death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From start of study drug administration up to 7 days after the last dose (up to Day 20)

  2. Number of Participants Based on Severity of TEAE

    Severity of a TEAEs were determined by following criteria: Mild: event that did not generally interfere with usual activities of daily living; Moderate: event that interfere with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupt usual activities of daily living, significantly affects clinical status, or might require intensive therapeutic intervention.

    Time frame: From start of study drug administration up to 7 days after the last dose (up to Day 20)

  3. Number of Participants Based on Causality of TEAEs

    Causality of TEAEs to the study medication was assessed using the following categories: Related: An AE that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which a causal relationship was at least a reasonable possibility, that is, the relationship cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, might also be responsible; Not Related: An AE that did not follow a reasonable temporal sequence from administration of a drug and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments.

    Time frame: From start of study drug administration up to 7 days after the last dose (up to Day 20)

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values

    Vital signs included body temperature (oral or tympanic measurement), respiratory rate, blood pressure \[systolic blood pressure (SBP) and diastolic blood pressure (DBP)\], and pulse (beats per minute). The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in vital signs values were reported.

    Time frame: Baseline to Day 13

  5. Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiograms (ECG) Values

    ECGs was performed with participants in a supine position. All ECG tracings were reviewed by the investigator or designee. Number of participants with clinically significant change from baseline in ECG values were reported.

    Time frame: Baseline to Day 13

  6. Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

    The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in laboratory values (hematology, serum chemistry, and urinalysis) were reported.

    Time frame: Baseline to Day 13

  7. Number of Participants With Clinically Significant Change From Baseline in Physical Examination

    Physical examination included the following body systems: (1) respiratory system; (2) cardiovascular system; (3) nervous system (4) dermatologic system; and (5) gastrointestinal system. The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in physical examination values were reported.

    Time frame: Baseline to Day 13

07

Results

Posted Aug 6, 2024

Participant flow

Participants took part in the study at single investigative site in the United States from 25 May 2023 to 26 June 2023.

Treatment Period 1 (2 Days)
Participant flow — Treatment Period 1 (2 Days)
MilestoneTreatment Sequence 1: (Treatment A + Treatment B + Treatment C)Treatment Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Treatment Sequence 6: (Treatment C + Treatment B + Treatment A)
Started444444
Completed444444
Not completed000000
Washout Period 1 (4 Days)
Participant flow — Washout Period 1 (4 Days)
MilestoneTreatment Sequence 1: (Treatment A + Treatment B + Treatment C)Treatment Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Treatment Sequence 6: (Treatment C + Treatment B + Treatment A)
Started444444
Completed444444
Not completed000000
Treatment Period 2 (2 Days)
Participant flow — Treatment Period 2 (2 Days)
MilestoneTreatment Sequence 1: (Treatment A + Treatment B + Treatment C)Treatment Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Treatment Sequence 6: (Treatment C + Treatment B + Treatment A)
Started444444
Completed444444
Not completed000000
Washout Period 2 (4 Days)
Participant flow — Washout Period 2 (4 Days)
MilestoneTreatment Sequence 1: (Treatment A + Treatment B + Treatment C)Treatment Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Treatment Sequence 6: (Treatment C + Treatment B + Treatment A)
Started444444
Completed444444
Not completed000000
Treatment Period 3 (2 Days)
Participant flow — Treatment Period 3 (2 Days)
MilestoneTreatment Sequence 1: (Treatment A + Treatment B + Treatment C)Treatment Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Treatment Sequence 6: (Treatment C + Treatment B + Treatment A)
Started444444
Completed444444
Not completed000000

Outcome measures

PrimaryCmax: Maximum Observed Plasma Concentration for TAK-227
Time frame:
Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for TAK-227
nanogram per milliliter (ng/mL)Treatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
Cmax: Maximum Observed Plasma Concentration for TAK-227464.4 ± 89.8190.9 ± 50.6370.0 ± 102.6
PrimaryAUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-227
Time frame:
Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter(ng*hr/mL)
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-227
nanogram*hour per milliliter(ng*hr/mL)Treatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-2271582 ± 65.9969.2 ± 51.21056 ± 53.0
PrimaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-227
Time frame:
Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter(ng*hr/mL)
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-227
nanogram*hour per milliliter(ng*hr/mL)Treatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-2271708 ± 52.0983.7 ± 50.81070 ± 51.8
SecondaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant who had signed the informed consent form (ICF) to participate in a study; it did not necessarily have to have a causal relationship with the treatment. An SAE was any untoward medical occurrence that at any dose met one or more of the following criteria: resulted in death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From start of study drug administration up to 7 days after the last dose (up to Day 20)
Reported as:
Count of participants · Participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsTreatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
TEAEs452
Serious TEAEs000
SecondaryNumber of Participants Based on Severity of TEAE

Severity of a TEAEs were determined by following criteria: Mild: event that did not generally interfere with usual activities of daily living; Moderate: event that interfere with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupt usual activities of daily living, significantly affects clinical status, or might require intensive therapeutic intervention.

Time frame:
From start of study drug administration up to 7 days after the last dose (up to Day 20)
Reported as:
Count of participants · Participants
Number of Participants Based on Severity of TEAE
ParticipantsTreatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
Mild352
Moderate100
Severe000
SecondaryNumber of Participants Based on Causality of TEAEs

Causality of TEAEs to the study medication was assessed using the following categories: Related: An AE that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which a causal relationship was at least a reasonable possibility, that is, the relationship cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, might also be responsible; Not Related: An AE that did not follow a reasonable temporal sequence from administration of a drug and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments.

Time frame:
From start of study drug administration up to 7 days after the last dose (up to Day 20)
Reported as:
Count of participants · Participants
Number of Participants Based on Causality of TEAEs
ParticipantsTreatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
Related TEAEs332
Not Related TEAEs120
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs Values

Vital signs included body temperature (oral or tympanic measurement), respiratory rate, blood pressure \[systolic blood pressure (SBP) and diastolic blood pressure (DBP)\], and pulse (beats per minute). The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in vital signs values were reported.

Time frame:
Baseline to Day 13
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values
ParticipantsTreatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiograms (ECG) Values

ECGs was performed with participants in a supine position. All ECG tracings were reviewed by the investigator or designee. Number of participants with clinically significant change from baseline in ECG values were reported.

Time frame:
Baseline to Day 13
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiograms (ECG) Values
ParticipantsTreatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiograms (ECG) Values000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in laboratory values (hematology, serum chemistry, and urinalysis) were reported.

Time frame:
Baseline to Day 13
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
ParticipantsTreatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Physical Examination

Physical examination included the following body systems: (1) respiratory system; (2) cardiovascular system; (3) nervous system (4) dermatologic system; and (5) gastrointestinal system. The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in physical examination values were reported.

Time frame:
Baseline to Day 13
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examination
ParticipantsTreatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
Number of Participants With Clinically Significant Change From Baseline in Physical Examination000

Adverse events

Collected over From start of study drug administration up to 7 days after the last dose (up to Day 20). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: TAK-227 50 mg0/24 (0%)0/24 (0%)2/24 (8.3%)
Treatment B: TAK-227 50 mg0/24 (0%)0/24 (0%)0/24 (0%)
Treatment C: TAK-227 50 mg0/24 (0%)0/24 (0%)0/24 (0%)
Most frequent other events
Most frequent other events
EventTreatment A: TAK-227 50 mgTreatment B: TAK-227 50 mgTreatment C: TAK-227 50 mg
HeadacheNervous system disorders2/240/240/24

Baseline characteristics

The safety set included all participants who received at least one dose of the study drug and were included in the safety evaluations.

Age, Continuous
Age, Continuous(years)Treatment Sequence 1: (Treatment A + Treatment B + Treatment C)Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Sequence 6: (Treatment C + Treatment B + Treatment A)Total
Mean49.0 ± 6.3843.0 ± 10.2339.5 ± 4.2042.8 ± 8.1043.0 ± 7.7036.5 ± 10.4742.3 ± 8.19
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: (Treatment A + Treatment B + Treatment C)Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Sequence 6: (Treatment C + Treatment B + Treatment A)Total
Female23212111
Male21232313
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence 1: (Treatment A + Treatment B + Treatment C)Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Sequence 6: (Treatment C + Treatment B + Treatment A)Total
Hispanic or Latino43423319
Not Hispanic or Latino0102115
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence 1: (Treatment A + Treatment B + Treatment C)Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Sequence 6: (Treatment C + Treatment B + Treatment A)Total
American Indian or Alaska Native0000000
Asian0001001
Native Hawaiian or Other Pacific Islander0000000
Black or African American1000012
White34434321
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Treatment Sequence 1: (Treatment A + Treatment B + Treatment C)Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Sequence 6: (Treatment C + Treatment B + Treatment A)Total
United States44444424
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Treatment Sequence 1: (Treatment A + Treatment B + Treatment C)Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Sequence 6: (Treatment C + Treatment B + Treatment A)Total
Mean28.613 ± 2.168927.055 ± 3.469427.795 ± 4.608527.640 ± 2.733427.380 ± 3.207026.280 ± 2.057227.460 ± 2.8896
Height
Height(centimeter (cm))Treatment Sequence 1: (Treatment A + Treatment B + Treatment C)Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Sequence 6: (Treatment C + Treatment B + Treatment A)Total
Mean164.5 ± 8.43165.0 ± 10.03162.3 ± 12.71171.3 ± 11.15169.8 ± 15.65173.8 ± 6.65167.8 ± 10.72
Weight
Weight(kilogram (kg))Treatment Sequence 1: (Treatment A + Treatment B + Treatment C)Sequence 2: (Treatment B + Treatment C + Treatment A)Treatment Sequence 3: (Treatment C + Treatment A + Treatment B)Treatment Sequence 4: (Treatment A + Treatment C + Treatment B)Treatment Sequence 5: (Treatment B + Treatment A + Treatment C)Sequence 6: (Treatment C + Treatment B + Treatment A)Total
Mean77.43 ± 7.13574.18 ± 15.43674.07 ± 18.00780.78 ± 5.03880.00 ± 19.58879.33 ± 4.64077.63 ± 11.986
08

Study locations

1 site
  • Celerion, Inc.
    Tempe, Arizona 85283, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Jun 2023, 0 months.

Results were first posted in Aug 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2023
First posted
Apr 19, 2023
StartActual
May 25, 2023
Primary completionActual
Jun 19, 2023
CompletionActual
Jun 26, 2023
Results first posted
Aug 6, 2024
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05818956
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
May 25, 2023
Primary completion
Jun 19, 2023
Completion
Jun 26, 2023
Results posted
Aug 6, 2024
Last update
Aug 6, 2024

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZED1227

Start the discussion